Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7851 - 7875 of 8037 in total
Boron (B) is a chemical element with an atomic number 5 that belongs in the Period 2 and Group 13 in the periodic table. It is a low-abundant metalloid that is a poor electrical conductor at room temperature. Natural boron exists in 2 stable isotopes however pure boron is hard...
Experimental
Matched Description: … agents, insecticides, semiconductors, magnets, wood preservatives, and an additive in glass fibers of
Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV). Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers....
Investigational
Matched Description: … for Human Use (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of
Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Investigational
CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.
Investigational
Investigational
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
Investigational
Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.
Experimental
E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
Investigational
Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.
Investigational
Investigational
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.
Investigational
TRC093 is a recombinant humanized IgG1k monoclonal antibody.
Investigational
Investigational
Investigational
Human amniotic fluid is the liquid surrounding the human embryo and fetus. Physically, the fluid provides protection through cushioning. Chemically, the fluid provides protection through its inherent antibacterial properties. The fluid contains carbohydrates, proteins, lipids, electrolytes, urea, immunoglobulins, growth factors, and vitamins.[L16373,L16378]
Investigational
Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.
Investigational
Investigational
Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics. The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics.
Investigational
INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.
Investigational
Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
Investigational
Ronacaleret is a calcium-sensing receptor antagonist.
Investigational
XL418 is a novel anticancer compound.
Investigational
Displaying drugs 7851 - 7875 of 8037 in total